International Immunology, Vol. 13, No. 7, 951-958,
July 2001
© 2001 Japanese Society for Immunology
Combinations of dominant-negative class II transactivator, p300 or CDK9 proteins block the expression of MHC II genes
Correspondence to: B. M. Peterlin
The class II transactivator (CIITA) regulates not only the transcription of HLA-DR, -DQ, -DP, but also invariant chain, DMA and DMB genes. A hybrid mutant CIITA protein, which contained residues from positions 302 to 1130 in CIITA fused to the enhanced green fluorescent protein (EdCIITA), inhibited the function of the wild-type protein. EdCIITA extinguished the inducible and constitutive expression of MHC II genes in epithelial cells treated with IFN-
and B lymphoblastoid cells respectively. Also, it blocked T cell activation by superantigen. This inhibition correlated with the localization of EdCIITA but not CIITA in the cytoplasm of cells. However, when EdCIITA was co-expressed with a dominant-negative form of the nucleoporin Nup214/CAN, it also accumulated in the nucleus. These data suggest that EdCIITA not only competes with the wild-type protein for the binding to MHC II promoters but sequesters a critical co-factor of CIITA in the cytoplasm. CIITA also recruits the histone acetyltransferase cAMP responsive element binding protein (CREB) binding protein and positive transcription elongation factor b (p-TEFb) for the transcription of MHC II genes. Dominant-negative p300 (DNp300) or CDK9 (DNCDK9) proteins inhibited the function of CIITA and of the DRA promoter. Thus, combinations of EdCIITA and DNp300 and/or DNCDK9 proteins extinguished the transcription of MHC II genes. They might become useful for future genetic therapeutic approaches in organ transplantation and autoimmune diseases.
Keywords: class II transactivator, CREB binding protein, dominant-negative protein, enhanced green fluorescent protein, MHC II, positive transcription elongation factor b
Transmitting editor: T. Sasazuki
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S.-D. Chou, A. N. H. Khan, W. J. Magner, and T. B. Tomasi Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells Int. Immunol., November 1, 2005; 17(11): 1483 - 1494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Shan, Y. Zhuo, D. Chin, C. A. Morris, G. F. Morris, and J. A. Lasky Cyclin-dependent Kinase 9 Is Required for Tumor Necrosis Factor-{alpha}-stimulated Matrix Metalloproteinase-9 Expression in Human Lung Adenocarcinoma Cells J. Biol. Chem., January 14, 2005; 280(2): 1103 - 1111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Naves, A. M. Lennon, G. Barbieri, L. Reyes, G. Puga, L. Salas, V. Deffrennes, M. Rosemblatt, M. Fellous, D. Charron, et al. MHC class II-deficient tumor cell lines with a defective expression of the class II transactivator Int. Immunol., May 1, 2002; 14(5): 481 - 491. [Abstract] [Full Text] [PDF]
|
|